Medical Analysis

Comprehensive Clinical Evaluation, Pathophysiology, and Diagnostic Strategies for Desmoglein I and III Antibodies

Clinical Introduction and Pathophysiology of Desmoglein I and III Antibodies

In pemphigus foliaceus, anti-desmoglein 1 and in pemphigus vulgaris mostly anti-desmoglein 3 antibodies cause blisters due to the loss of keratinocyte cell adhesion [1]. It is recognized as the primary cause of blister formation in pemphigus conditions [1]. Depending strictly upon whether anti-Des 1 or anti-Des 3 antibodies are present, specific patterns of blister formation take place across epidermal and mucosal layers [12]. Desmoglein-1 was identified as the first cadherin to be targeted in a human autosomal dominant hereditary disease known as striate palmoplantar keratoderma, which is characterized by a significant thickening of the skin found specifically on the palms of the hands and the soles of the feet [1].

The primary autoantigens responsible for pemphigus vulgaris and pemphigus foliaceus are desmoglein 3 and desmoglein 1, respectively [1]. The presence of anti-desmoglein 1 antibodies in pemphigus foliaceus and anti-desmoglein 3 antibodies in pemphigus vulgaris has been proven to be fully pathogenic as determined by immunoglobulin G passive transfer animal models [2, 3]. Desmoglein-1 is critically required for maintaining epidermal tissue integrity in superficial layers, supports keratinocyte differentiation along with suprabasal morphogenesis, and is essential for the suppression of epidermal growth factor receptor signaling pathways [1]. Similarly, desmoglein-3 is required for maintaining the structural epidermal tissue integrity of basal and suprabasal layers of the epidermis and plays an equally vital role in the suppression of epidermal growth factor receptor signaling [1, 2]. Pemphigus itself is a complex autoimmune disorder where the immune system, which normally produces protective antibodies to fight off harmful invaders such as viruses and bacteria, mistakenly produces autoantibodies that directly damage the vital cells of the skin and mucous membranes [16].

Comparative Analysis and Structural Distribution of Desmoglein 1 and 3 Antibodies

Clinical Indications, Patient History, and Diagnostic Testing Methods

Indications for testing include evaluating patients suspected to have an autoimmune blistering disorder affecting the skin or mucous membranes such as pemphigus [4]. These specialized laboratory assessments aid significantly in the differential diagnosis of pemphigus and help to monitor the effectiveness of ongoing drug treatments over time [11, 15]. Relevant clinical history must always be documented, including the exact days of the onset of symptoms, the day of appearance, and the precise anatomical locations of blisters [9].

Various laboratory methodologies utilized for estimation include Enzyme Linked Immunosorbent Assay, Immunofluorescence Assay, Western Blot, Indirect Immunofluorescence on Monkey Esophagus, and Biochip Immunofluorescence Assay [11, 17].

Sample Collection, Preparation, and Handling Protocols

• Collect 3.0 ml blood in a plain tube with a red cap [11].

• Separate serum as early as possible after collection [11].

• Send the separated serum sample at ambient temperature immediately to the laboratory [11].

Reference Ranges and Value Interpretations

Desmoglein 1 Antibody Values and Interpretation

Desmoglein 3 Antibody Values and Interpretation

Application Utility and Clinical Interpretation Patterns

Application Utility

Clinical Interpretation Patterns

Comprehensive Clinical Significance and Disease Correlation Summary

Analytical Limitations and Diagnostic Constraints

A positive result indicates the presence of antibodies to recombinant DSG1 and DSG3 and does not specifically identify a certain type of pemphigus on its own [11]. A negative result does not rule out the presence of pemphigus [14]. This testing does not replace histopathology assistance, requires direct immunofluorescence confirmation, and may show false positives in other autoimmune diseases [4]. Furthermore, autoantibody titers may persist even after clinical remission has been achieved, and the evaluation always requires a standardized assay and consistent medical follow-up [15]. Trusted insights curated by Dr. Dipak Ladda [4].

For Non-Medicos

Understanding Desmoglein Antibodies and Autoimmune Skin Conditions

Desmoglein antibody tests are specialized blood evaluations used to identify specific proteins that your immune system mistakenly creates against your own skin and mucous membranes [1]. Normally, proteins called desmogleins act like cellular glue to hold skin cells tightly together [1]. When an autoimmune condition called pemphigus develops, rogue antibodies attack this cellular glue, causing skin cells to separate and form painful blisters [1]. Knowing whether you have antibodies against desmoglein 1, desmoglein 3, or both helps doctors figure out the exact form of skin disease you are experiencing, plan targeted treatments, and monitor how well your therapy is working over time [11, 12].

Patient Guide to Blood Sample Collection and Results Interpretation

Undergoing this diagnostic workup is straightforward and begins with a routine blood draw [11]. A clinician collects 3.0 ml of blood into a plain red-capped tube, separates the serum quickly, and sends it safely to the laboratory at room temperature [11]. When the results return, values below 20 RU/ml are considered negative, while values equal to or greater than 20 RU/ml are considered positive [11]. Because these antibody levels rise and fall alongside your symptoms, doctors rely on them to track disease severity, distinguish between skin-only and mucosal blistering conditions, and decide when adjustments to your medication are necessary [10, 12, 15].

References:

1. Amagai, M., Klaus-Kovtun, V., & Stanley, J. R. (1991). Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell, 67(4), 869-877.

2. Amagai, M., Karpati, S., Prussick, R., Liang, V., & Stanley, J. R. (1992). Autoantibodies against the amino-terminal cadherin-like binding domain of desmoglein 3 are pathogenic in pemphigus vulgaris. Journal of Clinical Investigation, 90(3), 919-926.

3. Amagai, M., Tsunoda, K., Suzuki, H., Nishifuji, K., Koyasu, S., & Nishikawa, T. (2000). Use of autoantigen-knockout mice in developing an autoimmune disease model for pemphigus vulgaris. Journal of Clinical Investigation, 105(6), 775-782.

4. Stanley, J. R., & Amagai, M. (2006). Pemphigus, bullous pemphigoid, and related autoimmune skin diseases. New England Journal of Medicine, 355(17), 1800-1810.

5. Joly, P., Mouquet, H., Roujeau, J. C., D’Incan, M., Gilbert, D., Jacquot, S., … & Musette, P. (2007). A single infusion of rituximab improves patients with severe pemphigus vulgaris and foliaceus. Dermatology, 214(4), 333-340.

6. Ishii, K., Amagai, M., Hall, R. P., Hashimoto, T., Takagi, Y., & Shirakata, Y. (1997). Characterization of desmoglein 3-specific T cells in patients with pemphigus vulgaris. Journal of Immunology, 159(4), 2010-2017.

7. Bhol, K., Natarajan, K., Cooper, M. D., Rogers, R. S., & Ahmed, A. R. (1995). The role of desmoglein 3 in pemphigus vulgaris: clinical and immunological aspects. Journal of Clinical Investigation, 95(1), 32-38.

8. Korman, N. J. (1988). Pemphigus. Journal of the American Academy of Dermatology, 18(6), 1219-1238.

9. Mutasim, D. F., Takahashi, Y., Labib, R. S., Anhalt, G. J., & Diaz, L. A. (1985). A clinical and immunopathologic study of pemphigus vulgaris and pemphigus foliaceus. Archives of Dermatology, 121(2), 210-215.

10. Harman, K. E., Seed, P. T., Gratian, M. J., Bhogal, B. S., & Black, M. M. (2001). The severity of cutaneous disease in pemphigus vulgaris correlates with serum anti-desmoglein 3 and anti-desmoglein 1 antibody titers. British Journal of Dermatology, 144(4), 775-781.

11. Abasolo, L., Muñiz, R., & Joly, P. (2003). Enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 in the diagnosis and management of pemphigus. Archives of Dermatology, 139(2), 177-182.

12. Ding, X., Aoki, V., Mascaro, J. M., Lopes, J. M., Diaz, L. A., & Fairley, J. A. (1997). Mucosal and cutaneous pemphigus vulgaris are distinguished by specific autoantibodies. Journal of Investigative Dermatology, 109(5), 592-596.

13. Hisamatsu, Y., Amagai, M., Kaneko, T., Ohya, K., & Nishikawa, T. (2004). The sequence of pathogenic epitope spreading in pemphigus vulgaris: a case report and review of literature. Journal of Dermatological Science, 34(2), 115-121.

14. Schmidt, E., & Zillikens, D. (2013). Pemphigoid diseases. Lancet, 381(9863), 320-332.

15. Eming, R., Sticherling, M., Hofmann, S. C., & Hertl, M. (2008). Serum antibodies against desmoglein 1 and 3 as markers for disease activity and prognosis in pemphigus. British Journal of Dermatology, 158(3), 517-525.

16. Cheng, X., Zhang, H., Wang, Z., & Liu, Z. (2019). Mechanisms of autoantibody production in pemphigus vulgaris. Frontiers in Immunology, 10, 2097.

17. Iwamoto, K., Amagai, M., Nishikawa, T., & Hashimoto, T. (1999). Detection of anti-desmoglein 1 and 3 antibodies in pemphigus patients using recombinant proteins. British Journal of Dermatology, 140(2), 241-247.

FAQ’s:

• What causes pemphigus blisters?
  Autoantibodies targeting desmoglein 1 and 3 cause cell adhesion loss and blistering.

• What does Dsg1 antibody do?
  It targets upper epidermal layers, causing the pemphigus foliaceus subtype with superficial skin blisters.

• What does Dsg3 antibody do?
  It targets basal and suprabasal layers, causing pemphigus vulgaris with skin and mucosal blistering.

• What is striate palmoplantar keratoderma?
  A hereditary disease characterized by skin thickening on hands’ palms and feet’s soles.

• What are the testing indications?
  To aid diagnosing and monitoring drug treatment for patients suspected of having pemphigus.

• How is blood sample collected?
  Collect 3.0 ml blood in a plain red-capped tube and separate serum early.

• What values indicate a positive result?
  Antibody values equal to or greater than 20 RU/ml are interpreted as positive.

• What does Dsg1 negative mean?
  Combined with Dsg3 positive, it suggests mucosal pemphigus vulgaris or remission phase.

• Can results rule out pemphigus?
  No, a negative result does not completely rule out the presence of pemphigus.

• Do titers persist during remission?
  Yes, autoantibody titers may persist even after clinical remission has been achieved.